Novo Nordisk Faces a Perfect Storm: Generics, Price Wars, and a Steep Valuation Gap

Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly's US market dominance, and Canada's first generic Ozempic approval signaling pricing risks.

The Danish pharmaceutical giant Novo Nordisk is navigating one of its most turbulent periods in years. While the market for weight-loss and diabetes drugs continues to expand at breakneck speed, the company’s stock has been battered, losing nearly 20% of its value since January. At roughly €36 per share, it sits far below its 52-week high, and the pressure is mounting from all sides—competition, pricing erosion, and a looming generic threat.

A Market Share Shift in the US

The battle for dominance in the lucrative GLP-1 market is tilting decisively toward Eli Lilly. In the United States, Lilly now commands roughly 60% of the market, leaving Novo Nordisk with just under 40%. The overall pie has grown by nearly a third, which cushions both players, but the shift in share is stark. Outside the US, the race is far closer, with the two companies splitting the international market almost evenly.

Novo Nordisk does hold a clear edge in oral therapies. Its pill-based weight-loss treatments generate over 18,000 weekly prescriptions, dwarfing Lilly’s newer rival product, which manages only a fraction of that volume. This strength in tablets could prove pivotal as the market evolves.

A Valuation Gap That Screams Opportunity—or Risk

The stock market is pricing the two rivals very differently. Novo Nordisk trades at a price-to-earnings ratio of just 12, while Eli Lilly commands a multiple of 26—more than double. That gap is well below Novo Nordisk’s historical average, and some analysts see it as a sign of deep undervaluation. The stock closed recently at around $42, a staggering 70% drop from its mid-2024 record high.

But the low valuation also reflects real headwinds. Management has warned that revenue and operating profit could fall by up to 13% on a currency-adjusted basis this year. That would mark the first annual decline in nine years, driven by intense price competition and the arrival of new generics.

The Canadian Generic Test

The most immediate threat comes from Canada, where Health Canada has authorized the first generic version of Ozempic, manufactured by Dr. Reddy’s Laboratories. The approval is limited to Type 2 diabetes and explicitly excludes the weight-loss drug Wegovy. Canada is the world’s second-largest market for semaglutide, and Novo Nordisk’s patent protection there expired in early January.

More generics are lining up. Sandoz and Teva have also filed applications, with Sandoz aiming for a June launch. Historical patterns suggest that a single generic typically drives prices down to 75% of the original, while three competitors can slash them to 35%. For now, the US core market remains insulated—key patents there don’t expire until the early 2030s—but Canada is being watched as a bellwether.

Analyst Evan Seigerman of BMO Capital Markets calls it a critical test case. Investors will scrutinize how the original product holds up against copycats, even if a global threat is not yet imminent.

Pipeline Progress Offers a Counterweight

Amid the competitive noise, Novo Nordisk is making strides in its pipeline. The drug Etavopivat, targeting sickle cell disease, delivered positive Phase 3 results, reducing painful crises by 27% and nearly doubling the time to the first event compared to placebo. The company plans to file for regulatory approval in the second half of the year.

This rare disease program provides a bright spot, but it is unlikely to offset the immediate pressures on the core business.

What to Watch on May 6

All eyes are now on Monday, when Novo Nordisk reports first-quarter results before the US market opens. Analysts expect earnings to decline by roughly 5%, and the report will offer the first hard data on pricing pressure and market share trends. A relative strength index of 23 signals that the stock is deeply oversold, but that alone does not guarantee a rebound.

Investors will also be watching two specific details: sales figures for the oral version of Wegovy, seen as a key indicator of future market position, and the company’s plans for the US Medicare market, which opens to new patients on July 1. The management must present concrete strategies for that critical demographic.

Meanwhile, Novo Nordisk is wrapping up a share buyback program, purchasing up to 3.8 billion Danish kroner worth of B-shares by May 4. The company is also expanding production, with a new insulin center under construction in Bangladesh.

The convergence of generic competition, price wars, and a steep valuation discount makes this a defining moment. The Q1 numbers will either validate the pessimism or provide the first glimmer of a turnaround.